PARI overexpression promotes genomic instability and pancreatic tumorigenesis

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2529-2539

  O'Connor, Kevin W ^a   Dejsuphong, Donniphat ^a   Park, Eunmi ^a   Nicolae, Claudia M ^b   Kimmelman, Alec C ^a   D'Andrea, Alan D ^a   Moldovan, George Lucian ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PARP BINDING PROTEIN GENE; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; TUMOR GENE; TUMOR PROMOTION; UPREGULATION;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMANS; MICE; PANCREATIC NEOPLASMS; S PHASE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876915012     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3313     Document Type: Article

References (45)

1. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41.
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
3. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer 2012;12: 68-78.
4. Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog 2012;51:14-24.
5. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
6. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012;481:287-94.
7. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012;2:41-6.
8. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;491:399-405.
9. Moldovan GL, D'Andrea AD. Howthe Fanconi anemia pathway guards the genome. Annu Rev Genet 2009;43:223-49.
10. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
11. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324:217.
12. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003;63:2585-8.
13. Jiao L, Hassan MM, Bondy ML, Wolff RA, Evans DB, Abbruzzese JL, et al. XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J Gastroenterol 2008;103:360-7.
14. Li D, Liu H, Jiao L, Chang DZ, Beinart G, Wolff RA, et al. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res 2006;66:3323-30.
15. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006;12: 5277-87.
16. Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, et al. Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 2010;18:499-509.
17. Hosokawa M, Takehara A, Matsuda K, Eguchi H, Ohigashi H, Ishikawa O, et al. Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. Cancer Res 2007;67:2568-76.
18. Kashiwaya K, Hosokawa M, Eguchi H, Ohigashi H, Ishikawa O, Shinomura Y, et al. Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis. Cancer Sci 2009;100:457-64.
19. Piao L, Nakagawa H, Ueda K, Chung S, Kashiwaya K, Eguchi H, et al. C12orf48, termed PARP-1 binding protein, enhances poly(ADPribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage. Genes Chromosomes Cancer 2011;50: 13-24.
20. Moldovan GL, Dejsuphong D, Petalcorin MI, Hofmann K, Takeda S, Boulton SJ, et al. Inhibition of homologous recombination by the PCNA-interacting protein PARI. Mol Cell 2012;45: 75-86.
21. Li YH, Wang X, Pan Y, Lee DH, Chowdhury D, Kimmelman AC. Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response. PLoS ONE 2012;7: E39588.
22. Mirchandani KD, McCaffrey RM, D'Andrea AD. The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly. DNA Repair (Amst) 2008;7:902-11.
23. Hochegger H, Dejsuphong D, Fukushima T, Morrison C, Sonoda E, Schreiber V, et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 2006;25:1305-14.
24. Tainsky MA, Krizman DB, Chiao PJ, Yim SO, Giovanella BC. PA-1, a human cell model for multistage carcinogenesis: Oncogenes and other factors. Anticancer Res 1988;8:899-913.
25. Elsasser HP, Lehr U, Agricola B, Kern HF. Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 1992;61: 295-306.
26. Sumi S, Beauchamp RD, Townsend CM Jr, Uchida T, Murakami M, Rajaraman S, et al. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 1992;103:982-9.
27. Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 2012;11:3837-50.
28. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7.
29. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
30. Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell 2007;129:665-79.
31. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011;25: 717-29.
32. Heyer WD, Ehmsen KT, Liu J. Regulation of homologous recombination in eukaryotes. Annu Rev Genet 2010;44:113-39.
33. Bakhoum SF, Compton DA. Chromosomal instability and cancer: A complex relationshipwith therapeutic potential. JClin Invest 2012;122: 1138-43.
34. Mladenov E, Iliakis G. Induction and repair of DNA double strand breaks: The increasing spectrum of non-homologous end joining pathways. Mutat Res 2011;711:61-72.
35. Sale JE, Lehmann AR, Woodgate R. Y-family DNA polymerases and their role in tolerance of cellular DNA damage. Nat Rev Mol Cell Biol 2012;13:141-52.
36. Pathania S, Nguyen J, Hill SJ, Scully R, Adelmant GO, Marto JA, et al. BRCA1 is required for postreplication repair after UV-induced DNA damage. Mol Cell 2011;44:235-51.
37. Helleday T. Pathways for mitotic homologous recombination in mammalian cells. Mutat Res 2003;532:103-15.
38. Mao Z, Bozzella M, Seluanov A, Gorbunova V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair (Amst) 2008;7:1765-71.
39. Marini V, Krejci L. Srs2: The "Odd-Job Man" in DNA repair. DNA Repair (Amst) 2010;9:268-75.
40. Vaze MB, Pellicioli A, Lee SE, Ira G, Liberi G, Arbel-Eden A, et al. Recovery from checkpoint-mediated arrest after repair of a double-strand break requires Srs2 helicase. Mol Cell 2002;10: 373-85.
41. Petermann E, Orta ML, Issaeva N, Schultz N, Helleday T. Hydroxyureastalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell 2010;37:492-502.
42. Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M. Doublestrand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 2011;145:529-42.
43. Errico A, Deshmukh K, Tanaka Y, Pozniakovsky A, Hunt T. Identification of substrates for cyclin dependent kinases. Adv Enzyme Regul 2010;50:375-99.
44. Saponaro M, Callahan D, Zheng X, Krejci L, Haber JE, Klein HL, et al. Cdk1 targets Srs2 to complete synthesis-dependent strand annealing and to promote recombinational repair. PLoS Genet 2010;6:e1000858.
45. Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M, et al. CDKdependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 2005;434:598-604.